Therapeutic Approaches to Epstein-Barr Virus Cancers

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2022 Sep 29

PMID 36174496

Authors

Samantha S Soldan

Troy E Messick

Paul M Lieberman

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers.

Citing Articles

USP7 Inhibitors Destabilize EBNA1 and Suppress Epstein-Barr Virus Tumorigenesis.

Chen C, Addepalli K, Soldan S, Castro-Munoz L, Preston-Alp S, Patel R J Med Virol. 2025; 97(1):e70168.

PMID: 39821265 PMC: 11740287. DOI: 10.1002/jmv.70168.

Possible viral agents to consider in the differential diagnosis of blepharoconjunctivitis.

Musa M, Bale B, Suleman A, Aluyi-Osa G, Chukwuyem E, DEsposito F World J Virol. 2024; 13(4):97867.

PMID: 39722756 PMC: 11551683. DOI: 10.5501/wjv.v13.i4.97867.

Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.

Davis M, Anders N, Colevas A, Messick T, Rudek M Biomed Chromatogr. 2023; 38(2):e5775.

PMID: 37942577 PMC: 11027104. DOI: 10.1002/bmc.5775.

EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.

Monaco M, Soldan S, Su C, Clauze A, Cooper J, Patel R Neurol Neuroimmunol Neuroinflamm. 2023; 10(5).

PMID: 37562974 PMC: 10414776. DOI: 10.1212/NXI.0000000000200149.

Tabelecleucel: First Approval.

Keam S Mol Diagn Ther. 2023; 27(3):425-431.

PMID: 37016096 DOI: 10.1007/s40291-023-00648-z.

References

Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V . Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012; 72(5):1116-25. DOI: 10.1158/0008-5472.CAN-11-3399. View

Fares S, Spiess K, Olesen E, Zuo J, Jackson S, Kledal T . Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation. mBio. 2019; 10(1). PMC: 6336419. DOI: 10.1128/mBio.01707-18. View

Doubrovina E, Oflaz-Sozmen B, Prockop S, Kernan N, Abramson S, Teruya-Feldstein J . Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2011; 119(11):2644-56. PMC: 3311278. DOI: 10.1182/blood-2011-08-371971. View

Zhu J, Kamara S, Cen D, Tang W, Gu M, Ci X . Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells. Cell Death Dis. 2020; 11(4):213. PMC: 7113277. DOI: 10.1038/s41419-020-2410-7. View

Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M . Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005; 23(35):8942-9. DOI: 10.1200/JCO.2005.02.6195. View

Yiu S, Hui K, Munz C, Lo K, Tsao S, Kao R . Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma. Cancers (Basel). 2019; 11(12). PMC: 6966612. DOI: 10.3390/cancers11121871. View

Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V . CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. Mol Ther Oncolytics. 2020; 18:504-524. PMC: 7479496. DOI: 10.1016/j.omto.2020.08.005. View

Bochkarev A, Barwell J, Pfuetzner R, Bochkareva E, Frappier L, Edwards A . Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 1996; 84(5):791-800. DOI: 10.1016/s0092-8674(00)81056-9. View

Cohen J . Vaccine Development for Epstein-Barr Virus. Adv Exp Med Biol. 2018; 1045:477-493. PMC: 6328312. DOI: 10.1007/978-981-10-7230-7_22. View

10.

Kamara S, Guo Y, Mao S, Ye X, Li Q, Zheng M . Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma. Appl Microbiol Biotechnol. 2021; 105(19):7283-7293. DOI: 10.1007/s00253-021-11559-6. View

11.

Willis E, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato P . Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017; 35(52):7231-7239. PMC: 5739308. DOI: 10.1016/j.vaccine.2017.11.013. View

12.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

13.

Murata T, Sato Y, Kimura H . Modes of infection and oncogenesis by the Epstein-Barr virus. Rev Med Virol. 2014; 24(4):242-53. DOI: 10.1002/rmv.1786. View

14.

Saito M, Kono K . Landscape of EBV-positive gastric cancer. Gastric Cancer. 2021; 24(5):983-989. DOI: 10.1007/s10120-021-01215-3. View

15.

Finerty S, Tarlton J, Mackett M, Conway M, Arrand J, Watkins P . Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol. 1992; 73 ( Pt 2):449-53. DOI: 10.1099/0022-1317-73-2-449. View

16.

Cui X, Cao Z, Chen Q, Arjunaraja S, Snow A, Snapper C . Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine. 2016; 34(34):4050-5. DOI: 10.1016/j.vaccine.2016.06.021. View

17.

Andrei G, Trompet E, Snoeck R . Novel Therapeutics for Epstein⁻Barr Virus. Molecules. 2019; 24(5). PMC: 6429425. DOI: 10.3390/molecules24050997. View

18.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

19.

Bochkarev A, Barwell J, Pfuetzner R, Furey Jr W, Edwards A, Frappier L . Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell. 1995; 83(1):39-46. DOI: 10.1016/0092-8674(95)90232-5. View

20.

Shannon-Lowe C, Rickinson A . The Global Landscape of EBV-Associated Tumors. Front Oncol. 2019; 9:713. PMC: 6691157. DOI: 10.3389/fonc.2019.00713. View